The global live biotherapeutics products and microbe CDMO market size was valued at USD 14.3 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 41.3% from 2023 to 2030. The rising importance of the potential advantages of live biotherapeutic products (LBPs) and microbiome-based therapeutics in treating a variety of diseases, including inflammatory bowel disease, cancer, and neurological disorders, among patients and healthcare providers is the prime factor that propels market growth. Furthermore, increasing prevalence of chronic diseases and the growing demand for personalized medicine are also contributing to the expansion of the market.
CDMOs specializing in these fields have the expertise and infrastructure to support the development and manufacturing of these complex therapies, which require specialized equipment and facilities. As a result, pharmaceutical and biotech companies can outsource their production to CDMOs, allowing them to focus on research and development.
Moreover, there is a growing interest in LBPs and the microbiome as potential therapeutic agents, leading to increased research and development activities in these areas. This has resulted in a greater demand for CDMOs with expertise in these fields. Advances in sequencing technologies and bioinformatics have allowed for a deeper understanding of the microbiome and its role in health and disease. This has enabled the development of more targeted and effective live biotherapeutic products and microbiome-based therapies.
Moreover, regulatory bodies, such as the FDA, have recognized the potential of live biotherapeutic products and the microbiome and have provided guidance on the development and approval of these products. This has increased investor confidence and encouraged companies to invest in the development of these products. Overall, the LBPs and microbiome CDMO market is expected to experience significant growth in the coming years due to these drivers and the increasing interest in these innovative therapies.
The C.difficle dominated the market and held 83.6% of the market share in 2022. On the basis of application, the live biotherapeutic products and microbiome CDMO industry is segmented into C.difficle, Crohns disease, IBS, Diabetes, and Others. C. difficile is a bacterium that is found in the human gut microbiome and can cause severe diarrhea and colitis, particularly in people who have recently taken antibiotics. In recent years, there has been growing interest in using live biotherapeutic products (LBPs) to treat a range of diseases, including those related to the gut microbiome.
Live biotherapeutics products are living organisms, such as bacteria or viruses, that are used to prevent or treat diseases. C. difficile is one of the organisms that can be used as an LBP, and there has been some research into its potential use for treating C. difficile infections. As research into the human microbiome and the potential applications of LBPs continues to grow, it is likely that the market will show more interest in the use of C. difficile and other organisms for therapeutic purposes.
North America held dominant share of 79.2% in 2022, primarily due to the presence of key players and increasing investments in research and development activities in this region. The growing demand for effective treatments for various diseases such as C.difficile, Crohn's disease, and IBS, has also contributed to the market growth in North America.
Moreover, the region has a large number of established pharmaceutical and biotech companies with expertise in the development and commercialization of biologic products, including live biotherapeutic products and microbiome-based therapies. Additionally, the region has a well-established regulatory framework for biopharmaceuticals, which provides a stable environment for companies to develop and manufacture these products. Adding to it, North America has a strong research infrastructure, including top universities and research institutions, that drive innovation in the field. This has led to the development of cutting-edge technologies and techniques that are used in the production of live biotherapeutic products and microbiome-based therapies.
Market players are undertaking various strategic initiatives such as partnerships, collaborations, mergers and acquisitions, and geographic expansion, aiming to strengthen their service portfolio, and provide a competitive advantage. Some of the prominent players in the global live biotherapeutic products and microbiome CDMO market include:
Assembly Biosciences, Inc.
Wacker Chemie AG
Market size value in 2023
USD 31.8 million
Revenue forecast in 2030
USD 358.0 million
CAGR of 41.3% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million, and CAGR from 2023 to 2030
Revenue forecast, company share, competitive landscape, growth factors and trends
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled
Arrant Bio; 4D Pharma; Cerbios; Biose Industrie; Assembly Bioscience Inc.; Wacker Chemie AG; Quay Pharmaceuticals; NIZO; Lonza; Inpac Probiotics
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global live biotherapeutic products and microbiome CDMO market report on the basis of application, and region:
Application Outlook (Revenue, USD Million, 2018 - 2030)
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global live biotherapeutics products and microbiome CDMO market size was estimated at USD 14.3 million in 2022 and is expected to reach USD 31.8 million in 2030.
b. The global live biotherapeutics products and microbiome CDMO market is expected to grow at a compound annual growth rate of 41.3% from 2023 to 2030 to reach USD 358.0 million by 2030.
b. North America dominated the live biotherapeutics products and microbiome CDMO market with a share of 79.2% in 2022. This is attributable to the presence of key players and increasing investments in research and development activities in this region.
b. Arrant Bio; 4D Pharma; Cerbios; Biose Industrie; Assembly Bioscience Inc.; Wacker Chemie AG; Quay Pharmaceuticals; NIZO; Lonza; Inpac Probiotics
b. The rising importance of the potential advantages of live biotherapeutic products and microbiome-based therapeutics in treating a variety of diseases, including inflammatory bowel disease, cancer, and neurological disorders, among patients and healthcare providers is the prime factor that propels market growth
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."